Mei Hou

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Medicine, Oncology, Pharmacology +11

Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications

Dan Cao, Mei Hou, Yong‐Song Guan et al. · BMC Cancer · 2009 · 245 citations · Full text

Medicine, Oncology, Pathology +17

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu et al. · PubMed · 2005 · 147 citations

Medicine, Oncology, Pharmacology +13

Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications

Hongfeng Gou, Xinchuan Chen, Jiang Zhu et al. · Journal of Experimental & Clinical Cancer Research · 2011 · 92 citations · Full text

Medicine, Oncology, Pathology +14